The role of second-look laparotomy in the long-term survival in ovarian cancer

Annals of Oncology

Volumn 8, Issue 7, 1997, Pages 643-648

  Tuxen, M K ^a   Strauss, G ^b   Lund, B ^b   Hansen, M ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

Author keywords

Ovarian cancer; Prognosis; Second look laparotomy; Survival

Indexed keywords

ADULT; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SECOND LOOK SURGERY; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0030854186     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008294522550     Document Type: Article

References (29)

1. Aabo K, Hald I, Hørbov S et al. A randomized study of single agent vs combination chemotherapy in FIGO stages IIb, III and IV ovarian adenocarcinoma. Eur J Cancer Clin Oncol 1985; 21: 475-81.
2. Lund B, Hansen M, Hansen HH et al. A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma. Ann Oncol 1990; 1: 134-40.
3. Lund B, Hansen M, Hansen OP et al. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1989; 7: 1469-73.
4. Lund B, Hansen M, Hansen OP et al. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1990; 8: 1226-30.
5. Strauss G, Lund B, Hansen M. Combined high-dose platinum and etoposide in previously untreated ovarian cancer patients with residual disease. Int J Gynecol Cancer 1996; 6: 410-4.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
7. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
8. De Gramont A, Drolet Y, Varette C et al. Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients. Eur J Cancer Clin Oncol 1989; 25: 451-7.
9. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL et al. Long-term survival in ovarian cancer. Eur J Cancer 1991; 27: 1367-72.
10. Del Campo JM, Felip E, Rubio D et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 1994; 53: 27-32.
11. Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994; 74: 656-63.
12. Gallup DG, Talledo E, Dudzinski MR et al. Another look at the second-assessment procedure for ovarian epithelial carcinoma. Am J Obstet Gynecol 1987; 157: 590-6.
13. Charmichael JA, Shelley WE, Brown LB et al. A predictive index of cure versus no cure in advanced ovarian carcinoma patients replacement of second-look laparotomy as a diagnostic test. Gynecol Oncol 1987; 27: 269-78.
14. Ghatage P, Krepart GV, Lotocki R. Factor analysis of false-negative second-look laparotomy. Gynecol Oncol 1990; 36: 172-5.
15. Ho AG, Beller U, Speyer JL et al. A reassessment of the role of second-look laparotomy in advanced ovarian cancer. J Clin Oncol 1987; 5: 1316-21.
16. Chambers SK, Chambers JT, Kohorn EI et al. Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 1988; 72: 404-8.
17. Sonmendecker EWW. Is routine second-look laparotomy for ovarian cancer justified? Gynecol Oncol 1988; 31: 249-55.
18. Miller DS, Spirtos NM, Ballon SC et al. Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. Cancer 1992; 69: 502-10.
19. Lund B, Williamson P. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol 1990; 76: 617-22.
20. Podczaski ES, Stevens CW, Manetta A et al. Use of second-look laparotomy in the management of patients with ovarian epithelial malignancies. Gynecol Oncol 1987; 28: 205-14.
21. Lippman SM, Alberts DS, Slymen DJ et al. Second-look laparotomy in epithelial ovarian carcinoma. Cancer 1988; 61: 2571-7.
22. Hoskins WJ, Rubin SC, Dulaney E et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989; 34: 365-71.
23. Berek JS, Hacker NF, Lagasse LD et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983; 61: 189-93.
24. Wiltshaw E, Raju KS, Dawson I. The role of cytoreductive surgery in advanced carcinoma of the ovary: An analysis of primary and second surgery. Br J Obstet Gynaecol 1985; 92: 522-7.
25. Segna RA, Dottino PR, Mandeli JP et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993; 11: 434-9.
26. Sevelda P, Dittrich C, Salzer H. The value of second-look operation in patients with advanced epithelial ovarian carcinoma. Arch Gynecol Obstet 1989; 244: 79-86.
27. Van der Burg MEL, Van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629-34.
28. Chiara S, Lionetto R, Campora E et al. Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. Eur J Cancer 1995; 31A: 296-301.
29. Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer: Nonresponders to first-line therapy. Gynecol Oncol 1989; 33: 1-5.